- ►diabetesjournals.org M Laplante, H Sell, KL MacNaul, D Richard, … - Diabetes, 2003 - Am Diabetes Assoc This study sought to determine whether the adipose depot−specific
(subcutaneous [SF] vs. visceral [VF]) action of peroxisome
proliferator−activated receptor-γ (PPAR-γ) agonists on fat deposition ... Cited by 77 - Related articles - BL Direct - All 5 versions
- ►endojournals.org H Sell, JP Berger, P Samson, G Castriota, J … - Endocrinology, 2004 - Endocrine Soc The nuclear receptor peroxisome proliferator-activated receptor (PPAR) modulates
the expression of numerous genes involved in glucose and lipid homeostasis and
plays a critical role in adipocyte differentiation. Expression of ... Cited by 26 - Related articles - BL Direct - All 3 versions
- ►physiology.org M Berthiaume, H Sell, J Lalonde, Y Gelinas, … - … Journal of Physiology- Regulatory, Integrative and …, 2004 - Am Physiological Soc Peroxisome proliferator-activated receptor (PPAR ) agonists improve insulin
sensitivity and lipemia partly through enhancing adipose tissue proliferation
and capacity for lipid retention. The agonists also reduce local adipose ... Cited by 29 - Related articles - All 4 versions
M Laplante, WT Festuccia, G Soucy, Y … - Diabetes, 2006 - Am Diabetes Assoc In this study, we aimed to establish the mechanisms whereby peroxisome
proliferator–activated receptor γ (PPARγ) agonism brings about
redistribution of fat toward subcutaneous depots and away from visceral ... Cited by 42 - Related articles - BL Direct - All 4 versions
- Free from Publisher I Bogacka, H Xie, GA Bray, SR Smith - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Pioglitazone treatment increased the expression of genes involved in
glycerol-3-phosphate synthesis. The mRNA expression of PEPCK-C and
glycerol-3-phosphate dehydrogenase (GPDH) increased (P < 0.01) in patients ... Cited by 103 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org [PDF] F Picard, N Naimi, D Richard, Y Deshaies - Diabetes, 1999 - Am Diabetes Assoc Modulation of lipoprotein lipase (LPL) allows a tis- sue-specific partitioning
of triglyceride-derived fatty acids, and insulin is a major modulator of its
activity. The present studies were aimed to assess in rats the con- ... Cited by 47 - Related articles - BL Direct - All 5 versions
BF Burkey, M Dong, K Gagen, M Eckhardt, N … - Metabolism, 2000 - Elsevier Recent advances in the treatment of non-insulin-dependent diabetes mellitus
(NIDDM) include the use of thiazolidinediones (TZDs), agents that enhance
insulin action, in part, through an activation of adipose tissue peroxisome ... Cited by 16 - Related articles - BL Direct - All 4 versions
- ►jbc.org J Berger, M Tanen, A Elbrecht, A Hermanowski … - Journal of Biological Chemistry, 2001 - ASBMB Peroxisome proliferator-activated receptor- (PPAR ) has been shown to play an
important role in the regulation of expression of a subclass of adipocyte genes
and to serve as the molecular target of the thiazolidinedione (TZD) and ... Cited by 142 - Related articles - BL Direct - All 3 versions
H Kageyama, T Hirano, K Okada, T Ebara, A … - Biochemical and Biophysical Research …, 2003 - Elsevier Lipoprotein lipase (LPL), a key enzyme for triglyceride hydrolysis, is an
insulin-dependent enzyme and mainly synthesized in white adipose tissue (WAT)
and skeletal muscles (SM). To explore how pioglitazone, an enhancer of ... Cited by 31 - Related articles - BL Direct - All 4 versions
